ASX · AVE.AX
Avecho Biotechnology Limited
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
Loading market information…
ASX · NC6.AX · AUD
Stock price, earnings
Quote as of Oct 29, 2026, 02:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Nanollose Limited’s quoted price sits in the upper half of its reported 52-week range, 10.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nanollose Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nanollose Limited is an Australian biomaterials enterprise dedicated to the research, development, and commercialization of microbial nanocellulose technology. Its product line features Nullarbor Fibre, an innovative lyocell fibre produced without relying on trees, and Jelli Grow, an eco-friendly substitute for seed germination and cultivating plants. These materials find applications across various sectors, including textiles, nonwoven fabrics, and other industries. Established in 2014, the company's headquarters are situated in Nedlands, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
A$0.02A$0.00 (0.0%)
Neurotech International Limited’s quoted price sits in the upper half of its reported 52-week range, 19.05% below the high.
A$0.35+A$0.02 (+4.55%)
ImExHS Limited’s quoted price sits in the lower half of its reported 52-week range, 26.6% below the high.
A$0.05A$0.00 (0.0%)
BTC Health Limited’s quoted price sits in the lower half of its reported 52-week range, 27.14% below the high.
A$0.02-A$0.00 (-4.76%)
Althea Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
A$0.02A$0.00 (0.0%)
MedAdvisor Limited’s quoted price sits in the lower half of its reported 52-week range, 93.02% below the high.
A$0.04A$0.00 (0.0%)
Immuron Limited’s quoted price sits in the lower half of its reported 52-week range, 59.18% below the high.
A$0.03-A$0.00 (-3.57%)
Firebrick Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 63.51% below the high.
